首页|维格列汀联合二甲双胍治疗肥胖2型糖尿病患者的效果

维格列汀联合二甲双胍治疗肥胖2型糖尿病患者的效果

扫码查看
目的:观察维格列汀联合二甲双胍治疗肥胖 2 型糖尿病患者的效果.方法:选取 2021 年 1 月至 2023 年 1 月该院收治的102 例肥胖 2 型糖尿病患者进行前瞻性研究,按随机数字表法将其分为观察组和对照组各 51 例.对照组采用二甲双胍治疗,观察组在对照组基础上联合维格列汀治疗,比较两组治疗前后糖代谢指标[空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)]水平、脂代谢指标[总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)]水平,脂联素和趋化素水平,临床疗效,以及治疗期间不良反应发生率.结果:治疗后,观察组FBG、2hPG、HbA1c、TC、TG、LDL-C水平均低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05);观察组脂联素水平高于对照组,趋化素水平低于对照组,差异均有统计学意义(P<0.05);观察组治疗总有效率为 96.08%(49/51),高于对照组的 74.51%(38/51),差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:维格列汀联合二甲双胍治疗肥胖 2 型糖尿病患者可提高治疗总有效率和脂联素水平,改善脂代谢指标水平,降低糖代谢指标和趋化素水平,效果优于单纯二甲双胍治疗.
Effects of Vildagliptin combined with Metformin in treatment of obese patients with type 2 diabetes mellitus
Objective:To observe effects of Vildagliptin combined with Metformin in treatment of obese patients with type 2 diabetes mellitus.Methods:A prospective study was conducted on 102 obese patients with type 2 diabetes mellitus admitted to this hospital from January 2021 to January 2023.They were divided into observation group and control group according to the random number table method,51 cases in each.The control group was treated with Metformin,while the observation group was treated with Vildagliptin on the basis of that of the control group.The levels of glucose metabolism indexes[fasting blood glucose(FBG),2 h postprandial blood glucose(2hPG),glycosylated hemoglobin(HbA1c)],lipid metabolism indexes[total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C)and high-density lipoprotein cholesterol(HDL-C)],and the adiponectin and the chemotaxin before and after the treatment,the clinical efficacy,and the incidence of adverse reactions during the treatment were compared between the two groups.Results:After the treatment,the levels of FBG,2hPG,HbA1c,TC,TG and LDL-C in the observation group were lower than those in the control group,the level of HDL-C was higher than that in the control group,and the differences were statistically significant(P<0.05).The level of adiponectin in the observation group was higher than that in the control group,the level of chemotaxin was lower than that in the control group,and the differences were statistically significant(P<0.05).The total effective rate of treatment in the observation group was 96.08%(49/51),which was higher than 74.51%(38/51)in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Vildagliptin combined with Metformin in the treatment of the obese patients with type 2 diabetes mellitus can improve the total effective rate and the adiponectin levels,improve the levels of lipid metabolism indexes,and reduce the levels of glucose metabolism indexes and chemotaxins.Moreover,it is superior to single Metformin treatment.

Type 2 diabetes mellitusObesityVildagliptinMetforminAdiponectinChemotaxinGlycolipid metabolism

曹存英

展开 >

范县中医院,河南 濮阳 457500

2型糖尿病 肥胖 维格列汀 二甲双胍 脂联素 趋化素 糖脂代谢

2024

中国民康医学
中国社会工作协会

中国民康医学

影响因子:0.649
ISSN:1672-0369
年,卷(期):2024.36(2)
  • 14